KMD Bioscience Co., Ltd.
400-621-6806
Service Line：+1-315-239-3085
Address：FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：info@kmdbioscience.com
| Catalog Number | YR1632 |
|---|---|
| Product Name | Anti-RBD imdevimab(REGN10987)) |
| Molecular Name | Anti SARS-CoV-2(2019-nCoV) RBD imdevimab(REGN10987) |
| Alias | Anti-RBD Recombinant Antibody, Research Grade Anti SARS-CoV-2(2019-nCoV) RBD imdevimab(REGN10987) |
| Molecular Weight | 150 kDa |
| Target | RBD[SARS-CoV-2] |
| Isotype | Human IgG |
| Clonity | Monoclonal |
| Source | CHO Cells |
| Size | 1mg, 5mg |
| Concentration | 1mg/ml |
| Purity | >95% as determined by SDS-PAGE |
| Buffer | PBS, pH7.5 |
| Background | Casirivimab/imdevimab, sold under the brand name REGEN-COV, is an experimental medicine developed by the American biotechnology company Regeneron Pharmaceuticals. It is an artificial "antibody cocktail" designed to produce resistance against the SARS-CoV-2 coronavirus responsible for the COVID-19 pandemic. |
| Storage | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
| Note | This product is for research use only. |
FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：info@kmdbioscience.com
Hot Line： +1-315-239-3085
Technical Support：sales@kmdbiosci.com
